Special Features
A Spotlight on Progress and Pitfalls in NAFLD/MAFLD Studies, 2022
July 12, 2022
Nonalcoholic fatty liver disease (NAFLD) is now the leading etiology of chronic hepatitis in the Western world and the only one for which global prevalence is steadily rising over time. In the last years, there have been substantial advances in our understanding of the epidemiology, the (non-invasive) diagnostic methods (including omics technologies), the natural history and the major risk factors for advanced liver disease in NAFLD, including genetic variants and the gut microbiota. Promising results have also arisen from drugs targeting metabolic pathways involved in the progression of liver damage. Recently, international experts also proposed redefining NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD), but the impact of this name change on risk prediction of both hepatic and extra-hepatic outcomes is not known.
Integrative Omics Study for Clinical Liver Disease
May 24, 2022
As a major cause of morbidity and mortality, clinical liver disease (CLD) has become a severely increasing global burden due to its occupancy of health resources for patient treatment. Many pharmacological approaches (such as targeted therapy) or surgical techniques (such as live transplantation and associating liver partition and portal vein ligation for staged hepatectomy [ALPPS]) may help to improve the prognosis of patients with CLD. However, the underlying pathological mechanism of disease and the rationality of these therapies have yet to be revealed. A comprehensive understanding of the mechanisms of the occurrence and development of CLD and the relevant therapeutic approaches will support efforts for better prevention and therapy from the perspective of precision medicine.
Metabolic dysfunction-associated fatty liver disease (MAFLD)
March 24, 2021
Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as Nonalcoholic Fatty Liver Disease (NAFLD), is recently proposed nomenclature with a new set of diagnostic criteria. With an estimated 2 billion people being affected around the world, MAFLD signifies a growing global health burden, and such health challenge is expected to grow in the coming decade and especially among demographics with higher rate of obesity. Currently, MAFLD is recognized to increase the risk for higher severity in patients with the COVID-19.
Call for Papers for Special Issue ‘Coronavirus Disease (COVID-19) and the Liver’
June 3, 2020
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), is now a global pandemic, but a huge knowledge gap remains about the effects of this novel virus on the human body. Because angiotensin-converting enzyme 2 (ACE2), the reported receptor for SARS-CoV-2, is highly expressed in almost the entire gastrointestinal tract, a significant portion of patients develop elevated liver enzyme levels and gastrointestinal symptoms, but the underlying pathophysiology is obscure.
Author Interview: Thomas McQuaid
July 20, 2017
Author of "Sofosbuvir, a Significant Paradigm Change in HCV Treatment"
Author Interview: Lucija Virovic Jukic
May 5, 2017
Author of "Hepatitis C Virus, Insulin Resistance, and Steatosis"
Author Interview: Ashwani Singal
April 7, 2017
Author of "Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases"
Author Interview: Rolf Teschke
April 7, 2017
Interview regarding recent developments of Traditional Chinese Medicine Induced Liver Injury
  • Copyright © 2022 JCTH. All Rights Reserved.
  • Published by Xia & He Publishing Inc.
  • Address: 14090 Southwest Freeway, Suite 300, Sugar Land, Texas 77478, USA
  • Email: service@xiahepublishing.com